Dyspnea on exertion differentials

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

I now have comprehensive material from Harrison's (dedicated dyspnea chapter) and Rosen's Emergency Medicine. Here is the full differential:

Dyspnea on Exertion — Differential Diagnosis

Dyspnea on exertion (DOE) is breathlessness provoked by physical effort. Pulmonary and cardiac etiologies account for ~85% of chronic dyspnea cases. The differential spans multiple systems, organized below by urgency and category.

Cardiac Causes

Condition	Key Features
Heart failure (systolic or diastolic)	Most common; orthopnea, PND, S3 gallop, elevated BNP
Myocardial infarction / ischemia	DOE as anginal equivalent; especially in diabetics/elderly women
Valvular heart disease	Aortic stenosis (exertional syncope triad), mitral stenosis/regurgitation
Cardiomyopathy	Dilated, hypertrophic (HCM — exertional DOE ± syncope), restrictive
Cardiac tamponade	Elevated JVP, pulsus paradoxus, muffled sounds
Pulmonary arterial hypertension	Right heart strain; consider in HIV, CTD, chronic liver disease
Arrhythmia	Palpitations + DOE; AF, SVT, heart block
Congenital heart disease	In younger patients; shunts, uncorrected lesions

Pulmonary Causes

Condition	Key Features
COPD	Chronic progressive DOE; smoking history; obstructive pattern on PFTs
Asthma	Variable airflow obstruction; wheezing, chest tightness; worse with exercise/cold air
Interstitial lung disease (ILD/IPF)	Bibasilar crackles, restrictive pattern, GGOs on HRCT
Pulmonary embolism (PE)	Acute DOE; tachycardia, hypoxia, pleuritic chest pain; risk factors (DVT, immobility, malignancy)
Pulmonary hypertension	Exertional DOE, fatigue, syncope; right heart strain on ECG/echo
Pleural effusion	Dullness to percussion, reduced breath sounds at base
Pneumonia	Infectious prodrome, fever, consolidation on CXR
Pneumothorax	Sudden onset; may be exertional in young tall males (spontaneous); absent breath sounds
Upper airway obstruction	Stridor, monophonic wheeze; neoplasm, foreign body, tracheal stenosis
Obesity hypoventilation / sleep apnea	BMI >30, daytime somnolence, hypercapnia
Cor pulmonale	RV failure secondary to lung disease

Cardiovascular Overlap

Condition	Notes
Deconditioning	Extremely common; diagnosis of exclusion; normal workup
Anemia	High-output state; pallor, tachycardia, reduced Hgb
Pulmonary edema (cardiogenic or non-cardiogenic/ARDS)	Bilateral crackles, hypoxia, frothy sputum

Metabolic / Hematologic

Condition	Notes
Anemia	Fatigue, pallor; low Hgb/Hct
Metabolic acidosis	Compensatory tachypnea (Kussmaul breathing); check electrolytes, lactate, ABG
Hyperthyroidism	High-output cardiac state; tremor, weight loss, palpitations
Obesity	Increased work of breathing; often multifactorial

Neuromuscular

Condition	Notes
Myasthenia gravis	Fatigable weakness; bulbar symptoms
ALS / diaphragm weakness	Orthopnea in recumbency (paradoxical — worse lying flat due to diaphragm); FVC reduced
Guillain-Barré	Ascending weakness + DOE
Myopathies	Inflammatory (dermatomyositis, polymyositis) or hereditary

Psychiatric

Condition	Notes
Panic disorder / anxiety	Diagnosis of exclusion; hyperventilation syndrome; normal O₂ sat
Somatization	Chronic, variable; discordant exam

Approach by Onset

Onset	Think...
Acute	PE, pneumothorax, acute MI, acute HF exacerbation, anaphylaxis, arrhythmia
Subacute	Pneumonia, pericarditis, pleural effusion
Chronic / progressive	COPD, ILD, HF, valvular disease, PAH, anemia, deconditioning

Diagnostic Anchors

Orthopnea + PND → Heart failure
Exertional syncope or systolic murmur → HCM or aortic stenosis
Pleuritic chest pain + risk factors → PE
Bibasilar crackles + clubbing → ILD
Wheezing + reversibility → Asthma
Hypoxia disproportionate to symptoms → Shunt, PE, ILD
Normal workup → Deconditioning, anxiety, anemia

Sources: Harrison's Principles of Internal Medicine 22E, Ch. 39 (Dyspnea) — p. 311; Rosen's Emergency Medicine, Ch. 21 (Dyspnea) — Table 21.1; Fishman's Pulmonary Diseases, Ch. 32 (Unexplained Dyspnea)

Can lmwh be given in stemi patient with ckd

Reading File

Finding Sources

Reading File

I now have detailed, sourced information. Here is the full answer:

LMWH (Enoxaparin) in STEMI with CKD

Short Answer

Yes, but with important caveats — dose must be adjusted based on renal function, and in severe CKD (CrCl <30 mL/min), UFH is generally preferred.

Why CKD Matters

LMWH (primarily enoxaparin) is renally cleared (~40% excreted unchanged in urine). In CKD, reduced clearance leads to drug accumulation, prolonged anti-Xa activity, and significantly elevated bleeding risk. CKD patients with STEMI already have higher baseline mortality at every stage of kidney disease.

Enoxaparin Dosing in STEMI by Renal Function

Scenario	Standard Dose	CKD Adjustment
STEMI, age <75, CrCl ≥30	30 mg IV bolus → 1 mg/kg SC q12h	No adjustment needed
STEMI, age ≥75, CrCl ≥30	No IV bolus → 0.75 mg/kg SC q12h	Reduced dose (age-related accumulation)
STEMI, any age, CrCl <30	Avoid standard dosing	Reduce to 1 mg/kg SC once daily (q24h instead of q12h)
STEMI + fibrinolysis, serum Cr >2.5 mg/dL (men) or >2.0 mg/dL (women)	Enoxaparin not recommended	Use UFH instead

When to Switch to UFH

UFH is preferred over LMWH in STEMI with CKD when:

CrCl <30 mL/min (severe CKD / eGFR Stage 4–5)
Serum creatinine >2.5 mg/dL in men or >2.0 mg/dL in women (particularly if fibrinolysis is used)
Primary PCI is planned — many operators prefer UFH for PCI regardless of renal function, due to real-time monitoring with activated clotting time (ACT) in the cath lab
Dialysis-dependent patients — LMWH accumulation is unpredictable; UFH is standard

UFH advantages in CKD: hepatically cleared, reversible with protamine, and monitorable in real time with aPTT or ACT.

Bivalirudin (Alternative)

A direct thrombin inhibitor; can be used in STEMI patients undergoing PCI
Agent of choice in HIT
Dose adjustment required in CKD: reduced infusion rate
Less studied in the STEMI + fibrinolysis context

Fondaparinux

Contraindicated if CrCl <30 mL/min (renally excreted; severe accumulation risk)
Use with caution at CrCl 30–50 mL/min
Not generally first-line for STEMI

Practical Summary

CrCl	Preferred Anticoagulant in STEMI
≥30 mL/min	Enoxaparin (dose-adjusted if age ≥75) or UFH
<30 mL/min	UFH (preferred); if LMWH used, reduce to q24h dosing
Dialysis	UFH
Primary PCI	UFH or bivalirudin (enoxaparin generally not recommended)

Sources: Washington Manual of Medical Therapeutics — p. 154 (STEMI anticoagulation); Braunwald's Heart Disease — Table 101.5 (Antithrombotic Agents in CKD); Swanson's Family Medicine Review

UFH dose for patient with ckd with stemi

The previous search already retrieved the UFH dosing table from Braunwald's Heart Disease (Table 101.5) directly in my context. No new search needed.

UFH Dosing in STEMI with CKD

Key Point

UFH is not renally cleared — it is metabolized hepatically and does not accumulate in CKD. This is why it is preferred over LMWH in severe renal impairment.

UFH Doses in STEMI (from Braunwald's Table 101.5)

Clinical Context	UFH Dose
Primary PCI (no GPIIb/IIIa inhibitor)	60–100 units/kg IV bolus → Target ACT 250–350 sec
Primary PCI (with GPIIb/IIIa inhibitor)	50–70 units/kg IV bolus → Target ACT 200 sec
STEMI + fibrinolysis (streptokinase), weight <80 kg	800 units/hr infusion
STEMI + fibrinolysis (streptokinase), weight >80 kg	1000 units/hr infusion
STEMI + fibrinolysis (tPA/tenecteplase)	60–70 units/kg IV bolus (max 5000 units) → infusion at 12–15 units/kg/hr (max 1000 units/hr) → Target aPTT 50–75 sec

CKD-Specific Adjustment

Parameter	Recommendation
Starting bolus	50 units/kg IV (lower than standard, to reduce bleeding risk)
Maintenance infusion	18 units/kg/hr → adjust per aPTT
Monitoring	aPTT every 6 hours until therapeutic; target aPTT 50–75 sec (1.5–2.5× control)
Protamine reversal	Available if needed — key advantage in high-bleed-risk CKD patients

In CKD, the suggested starting dose is 50 units/kg bolus, then 18 units/kg/hr, with close aPTT monitoring per institutional protocol. — Braunwald's Heart Disease, Table 101.5

Why UFH is Preferred Over LMWH in Severe CKD (CrCl <30)

Not renally excreted → no accumulation
Real-time monitoring with aPTT (medical ward) or ACT (cath lab)
Fully reversible with protamine sulfate
Dose can be titrated precisely

Source: Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine — Table 101.5 (Antithrombotic Agents for ACS in CKD)

This is a shared conversation. Sign in to Orris to start your own chat.